Back

Spironolactone in patients with permanent atrial fibrillation, possible heart failure protective potential.

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Epidemiology of atrial fibrillation, miscellaneous Mechanisms for Heart Failure and Cardiac Complications ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Rafal Dabrowski

National Institute of Cardiology, Warsaw (Poland)

9 More presentations in this session

Presentation thumbnail
Circulating biomarkers of myocardial fibrosis and cellular apoptosis in patients with atrial fibrillation and heart failure with preserved ejection fraction
Associate Professor M. Dzeshka (Grodno, BY)
Abstract Slides
Presentation thumbnail
Left ventricular stiffness assessed by diastolic wall strain predicts infrequent atrial fibrillation
Doctor H. Kishima (Nishinomiya, JP)
Abstract Slides
Presentation thumbnail
Outcomes of heart failure with reduced ejection fraction (HFrEF) status post implantable cardioverter-defibrillator (ICD) presenting with HFrEF exacerbation with verses without atrial fibrillation(AF)
Doctor H. Arshad (Newark, US)
Presentation thumbnail
The impact of elective cardioversion for atrial fibrillation in heart failure patients
Doctor J. Graby (Bristol, GB)
Abstract
Presentation thumbnail
MOODS: a novel risk score to identify patients with atrial fibrillation and sleep apnoea
Doctor K. Kadhim (Adelaide, AU)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 4 - Epidemiology of atrial fibrillation, miscellaneous

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Atrial arrhythmias
thumbnail
Congress Session
Treatment strategies for atrial fibrillation in heart failure
thumbnail
Congress Session
How to manage atrial fibrillation in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources